clinical trial · NCT05053035
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Amyotrophic Lateral SclerosisAL001Placebo
brief summary
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
started
Sep 2, 2021
primary completion
Oct 28, 2022
completion
Oct 28, 2022
last updated
Jun 18, 2025
detailed description
This is a phase 2 double-blind, placebo-controlled trial to test the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in participants with C9orf72-associated Amyotrophic Lateral Sclerosis.
official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol